As mentioned above, since ipilimumab depletes CTLA4+ Tregs through ADCC, as one of the mechanisms for inducing anti-tumor immune response in melanoma patients that leads to induction of high therapeutic efficacy when administered with nivolumab [46,53], investigations for other drugs that selectively deplete eTregs are ongoing. Here, CTLA4 is linked to melanoma.